Medical treatment in children with central nervous system malformations.

[1]  P. Ryvlin,et al.  Can we predict refractory epilepsy at the time of diagnosis? , 2005, Epileptic disorders : international epilepsy journal with videotape.

[2]  E. Perucca.  Can drug resistance in epilepsy be minimized? Challenging commonly held beliefs. , 2005, Epileptic disorders : international epilepsy journal with videotape.

[3]  G. Holmes.  Effects of seizures on brain development: lessons from the laboratory. , 2005, Pediatric neurology.

[4]  Dieter Schmidt,et al.  Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms , 2005, Epilepsia.

[5]  F. Vigevano.  Topical Review: Levetiracetam in Pediatrics , 2005, Journal of child neurology.

[6]  P. Kwan,et al.  Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy , 2005, Epilepsia.

[7]  S. Seri,et al.  Topical Review: Intractable Seizures in Tuberous Sclerosis Complex: From Molecular Pathogenesis to the Rationale for Treatment , 2004, Journal of child neurology.

[8]  W. Löscher,et al.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family , 2005 .

[9]  J. Lewin,et al.  High‐resolution MRI Enhances Identification of Lesions Amenable to Surgical Therapy in Children with Intractable Epilepsy , 2004, Epilepsia.

[10]  S. Seri,et al.  Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy , 2004, Neurology.

[11]  W. Löscher,et al.  The chance of cure following surgery for drug-resistant temporal lobe epilepsy What do we know and do we need to revise our expectations? , 2004, Epilepsy Research.

[12]  E. Hirsch,et al.  [Refractory partial epilepsy: what are the neuropediatrician's criteria for drug resistance?]. , 2004, Revue neurologique.

[13]  S. Seri,et al.  Topical Review: Intractable Seizures in Tuberous Sclerosis Complex: From Molecular Pathogenesis to the Rationale for Treatment , 2004 .

[14]  P. Curatolo,et al.  Pharmacologic treatment of autism. , 2004, Journal of child neurology.

[15]  C. McDougle,et al.  Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[16]  S. A. Gromov,et al.  Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial , 2003, Epilepsy Research.

[17]  D. Goldstein,et al.  Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. , 2003, The New England journal of medicine.

[18]  T. Edgar.  Oral Pharmacotherapy of Childhood Movement Disorders , 2003, Journal of child neurology.

[19]  C. Ritch,et al.  Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement , 2002, Developmental medicine and child neurology.

[20]  W. Mitchell,et al.  Vigabatrin for infantile spasms. , 2002, Pediatric neurology.

[21]  C. McDougle,et al.  Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.

[22]  K. Haginoya,et al.  [Treatment with fluvoxamine against self-injury and aggressive behavior in autistic children]. , 2002, No to hattatsu = Brain and development.

[23]  P. Goodnick,et al.  Psychotropic drugs and the ECG: focus on the QTc interval , 2002, Expert opinion on pharmacotherapy.

[24]  E. Kossoff,et al.  Efficacy of the ketogenic diet for infantile spasms. , 2002, Pediatrics.

[25]  T. Maehara,et al.  Postoperative development of children after hemispherotomy , 2002, Brain and Development.

[26]  M Thom,et al.  Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. , 2002, Brain : a journal of neurology.

[27]  P. Curatolo,et al.  Vigabatrin for tuberous sclerosis complex , 2001, Brain and Development.

[28]  D. Parain,et al.  Vagal nerve stimulation in tuberous sclerosis complex patients. , 2001, Pediatric neurology.

[29]  J. Wheless,et al.  Vagus Nerve Stimulation in Children with Refractory Seizures Associated with Lennox–Gastaut Syndrome , 2001, Epilepsia.

[30]  T. Fukuda,et al.  [Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder]. , 2001, No to hattatsu = Brain and development.

[31]  I. Gilaberte,et al.  [Open study of fluoxetine in children with autism]. , 2000, Actas espanolas de psiquiatria.

[32]  M. Abel,et al.  Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy , 2000 .

[33]  S. Campbell,et al.  Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy , 2000 .

[34]  B. Handen,et al.  Efficacy of Methylphenidate Among Children with Autism and Symptoms of Attention-Deficit Hyperactivity Disorder , 2000, Journal of autism and developmental disorders.

[35]  B. Bourgeois,et al.  A Risk-Benefit Assessment of Therapies for Lennox-Gastaut Syndrome , 2000, Drug safety.

[36]  P. Genton.  When antiepileptic drugs aggravate epilepsy , 2000, Brain and Development.

[37]  C. McDougle,et al.  Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. , 1999, Journal of clinical psychopharmacology.

[38]  J. Osborne,et al.  Use of melatonin to treat sleep disorders in tuberous sclerosis , 1999, Developmental medicine and child neurology.

[39]  M. Aman,et al.  Atypical antipsychotics in persons with developmental disabilities , 1999 .

[40]  L. E. Arnold,et al.  Review of serotonergic agents and perseverative behavior in patients with developmental disabilities , 1999 .

[41]  Nirbhay N. Singh,et al.  Nutritional, dietary, and hormonal treatments for individuals with mental retardation and developmental disabilities , 1999 .

[42]  P. Uldall,et al.  Clinical experiences with topiramate in children with intractable epilepsy. , 1999, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[43]  S. Bhaumik,et al.  Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. , 2002, Journal of intellectual disability research : JIDR.

[44]  P. Genton,et al.  Lamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy , 1998, Epilepsia.

[45]  L. J. Barnhill,et al.  Olanzapine in PDD. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[46]  J. Overall,et al.  Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[47]  D. DeMaso,et al.  Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. , 1997, Journal of child and adolescent psychopharmacology.

[48]  M. Aman.  Stimulant drugs in the developmental disabilities revisited , 1996 .

[49]  B. Meldrum.  Update on the Mechanism of Action of Antiepileptic Drugs , 1996, Epilepsia.

[50]  P. Muglia,et al.  Clinical effects of clozapine on autistic disorder. , 1996, The American journal of psychiatry.

[51]  R. Guerrini.  Dysplasias of cerebral cortex and epilepsy , 1996 .

[52]  N. Barbaro,et al.  MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy , 1995, Epilepsia.

[53]  R. Snead,et al.  Paroxetine for self-injurious behavior. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.

[54]  B. Leventhal,et al.  Fluoxetine treatment of children and adults with autistic disorder and mental retardation. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.

[55]  J. Locascio,et al.  Repeated episodes of neuroleptic-related dyskinesias in autistic children. , 1991, Psychopharmacology bulletin.

[56]  O. Dulac,et al.  Vigabatrin in infantile spasms , 1990, The Lancet.

[57]  R. Perry,et al.  The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children , 1989, Journal of autism and developmental disorders.

[58]  R. Joynt,et al.  Dantrolene Sodium Suspension in Treatment of Spastic Cerebral Palsy , 1980, Developmental medicine and child neurology.

[59]  H. Engle,et al.  The Effect of Diazepam (Valium) in Children with Cerebral Palsy: A Double‐Blind Study , 1966, Developmental medicine and child neurology.